Newsfeeds Archive - Page 3 of 5

1 minute read

News

Pre-Clinical Data of Palatin’s Melanocortin Agonist Demonstrates Therapeutic Effects in Diabetic Retinopathy and Uveitis, International Journal of Molecular Sciences States

April 18, 7:34 AM

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor

PTN

1 minute read

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target

By Benzinga Newsdesk

February 16, 5:39 AM

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.

PTN

1 minute read

Earnings

Earnings Outlook For Palatin Technologies

By Benzinga Insights

February 14, 3:02 PM

Palatin Technologies (AMEX:PTN) is set to give its latest quarterly earnings report on Wednesday, 2023-02-15. Here’s what investors…

PTN

4 minute read

Reported Earlier, Frontiers In Immunology Publishes Pre-Clinical Study Of Palatin’s PL8177 Demonstrating Therapeutic Effects In Inflammatory Conditions

By Benzinga Newsdesk

January 11, 10:46 AM

- Collaboration with The William Harvey Research Institute and Queen Mary University of London - PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY,

PTN

9 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

December 23, 1:16 PM

OnFriday, 143 stocks hit new 52-week lows.

ACHR

18 minute read

Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

December 22, 2:13 PM

Thursday's session saw 329 companies set new 52-week lows.

ABNB

6 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

November 29, 12:04 PM

On Tuesday, 89 companies set new 52-week lows.

$APE

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

November 14, 6:06 AM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

1 minute read

Palatin Net Product Revenue For Prescriptions Dispensed Increased 20%

By Bill Haddad

October 13, 7:31 AM

Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J., Oct. 13, 2022

PTN

2 minute read

Earnings

Looking Into Palatin Technologies’s Return On Capital Employed

By Benzinga Insights

September 23, 10:03 AM

Palatin Technologies (AMEX:PTN) brought in sales totaling $770 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 67.3%, resulting in a loss of $12.77 million.

PTN